formerly mela sciences, strata skin sciences is a new company built by unconventional thinkers. a medical technology company that brings hope and help to the dermatology patient in all of us. it’s not just a device or a technology, it’s optimism for psoriasis, determination for improving patients’ lives, and advocacy for getting it right.
![STRATA Skin Sciences logo](https://files.capedge.com/10-K/0001051514-18-000012/image0.jpg)
Company profile
Ticker
SSKN
Exchange
Website
CEO
Dolev Rafaeli
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ELECTRO OPTICAL SCIENCES INC /NY, MELA SCIENCES, INC. /NY
SEC CIK
Corporate docs
IRS number
133986004
SSKN stock data
Latest filings (excl ownership)
8-K
Material Modifications to Rights of Security Holders
4 Jun 24
10-Q
2024 Q1
Quarterly report
15 May 24
8-K
STRATA Skin Sciences Reports First Quarter 2024 Financial Results and Provides a Corporate Update
15 May 24
10-K/A
2023 FY
Annual report (amended)
29 Apr 24
8-K
STRATA Skin Sciences Announces 1-for-10 Reverse Stock Split
26 Apr 24
10-K
2023 FY
Annual report
27 Mar 24
8-K
STRATA Skin Sciences Reports Fourth Quarter and Full-Year 2023 Earnings
27 Mar 24
8-K
STRATA Skin Sciences Announces Successful Amendment to Credit Agreement with MidCap Financial
26 Feb 24
8-K
Entry into a Material Definitive Agreement
21 Feb 24
8-K
STRATA Skin Sciences to Present Poster Showcasing Safety and Efficacy of TheraClear®X for Acne at Maui Derm 2024 Conference
8 Jan 24
Transcripts
SSKN
Earnings call transcript
2024 Q1
15 May 24
SSKN
Earnings call transcript
2023 Q4
27 Mar 24
SSKN
Earnings call transcript
2023 Q3
14 Nov 23
SSKN
Earnings call transcript
2023 Q2
9 Aug 23
SSKN
Earnings call transcript
2023 Q2
9 Aug 23
SSKN
Earnings call transcript
2023 Q1
15 May 23
SSKN
Earnings call transcript
2022 Q4
31 Mar 23
SSKN
Earnings call transcript
2022 Q3
10 Nov 22
SSKN
Earnings call transcript
2022 Q2
10 Aug 22
SSKN
Earnings call transcript
2022 Q1
12 May 22
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 6.57 mm | 6.57 mm | 6.57 mm | 6.57 mm | 6.57 mm | 6.57 mm |
Cash burn (monthly) | 515.67 k | (no burn) | 963.00 k | 742.25 k | 268.00 k | 42.17 k |
Cash used (since last report) | 1.42 mm | n/a | 2.64 mm | 2.04 mm | 735.69 k | 115.75 k |
Cash remaining | 5.16 mm | n/a | 3.93 mm | 4.53 mm | 5.84 mm | 6.46 mm |
Runway (months of cash) | 10.0 | n/a | 4.1 | 6.1 | 21.8 | 153.1 |
Institutional ownership, Q3 2023
49.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 27 |
Opened positions | 4 |
Closed positions | 3 |
Increased positions | 3 |
Reduced positions | 7 |
13F shares | Current |
---|---|
Total value | 6.30 bn |
Total shares | 17.38 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
22NW Fund | 5.37 mm | $3.12 mm |
22NW | 5.37 mm | $3.20 bn |
Nantahala Capital Management | 3.26 mm | $1.94 bn |
Renaissance Technologies | 1.08 mm | $642.00 k |
Vanguard | 858.20 k | $510.63 mm |
Essex Investment Management | 407.45 k | $242.43 mm |
Cannell Capital | 351.61 k | $209.00 k |
Geode Capital Management | 110.62 k | $65.85 mm |
Creative Planning | 100.01 k | $59.51 mm |
Perritt Capital Management | 100.00 k | $59.50 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Dec 23 | Shmuel Gov | SSKN Common Stock | Buy | Acquire P | No | No | 0.47 | 4,800 | 2.26 k | 20,000 |
1 Dec 23 | Shmuel Gov | SSKN Common Stock | Buy | Acquire P | No | No | 0.46 | 300 | 138.00 | 15,200 |
1 Dec 23 | Shmuel Gov | SSKN Common Stock | Buy | Acquire P | No | No | 0.45 | 562 | 252.90 | 14,900 |
1 Dec 23 | Shmuel Gov | SSKN Common Stock | Buy | Acquire P | No | No | 0.44 | 14,338 | 6.31 k | 14,338 |
21 Nov 23 | Christopher Lesovitz | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.5 | 337,500 | 168.75 k | 787,500 |
21 Nov 23 | Shmuel Gov | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.5 | 416,250 | 208.13 k | 971,250 |
16 Nov 23 | Samuel Rubinstein | Common Stock | Sell | Dispose S | No | No | 0.32 | 1,000 | 320.00 | 177,602 |
News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
16 May 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
15 May 24
Strata Skin Sciences Q1 2024 GAAP EPS $(0.10) Misses $(0.07) Estimate, Sales $6.754M Miss $6.912M Estimate
15 May 24
STRATA Skin Sciences Announces The Placement Of Six XTRAC Devices With Dermatology Clinics In Q1 Of 2024 That Are Considered "Comebacks"
30 Apr 24
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
29 Apr 24
Press releases
STRATA Skin Sciences Sponsors Webinars Featuring Leading Dermatologists Discussing Benefits of XTRAC® and TheraClear®X Devices
12 Jun 24
STRATA Skin Sciences' TheraClear®X Acne Therapy System Found to be Safe and Effective for Acne Lesions Across All Fitzpatrick Skin Types with Favorable Tolerability and Patient Satisfaction as Published in Peer Reviewed Journal
7 Jun 24
STRATA Skin Sciences to Participate in June Dermatology Conferences
4 Jun 24
STRATA Skin Sciences Surpasses 100 Domestic Installations of TheraClear®X Devices as of March 31, 2024
14 May 24
STRATA Skin Sciences to Participate in the Benchmark Healthcare House Call Virtual 1x1 Investor Conference
13 May 24